Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration
2026-06-01 19:00
Ebola disease in Democratic Republic of Congo: MSF scales up response to a rapidly evolving outbreak
2026-06-01 18:06
Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas
2026-06-01 17:50
Smartee Mandibular Advancement Repositioning Seminar Draws Active Clinical Dialogue in Tokyo
2026-06-01 15:06
China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA
2026-06-01 15:04
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
2026-06-01 13:51
Driving Innovation, Empowering Partners: ACROBiosystems Showcases Comprehensive CGT Solutions Anchored by GMP Capabilities at Bio Korea 2026
2026-06-01 13:30
Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
2026-06-01 12:00
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
2026-06-01 11:09
ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
2026-06-01 10:37
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
2026-06-01 08:15
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
2026-06-01 08:15
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
2026-06-01 08:00
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
2026-06-01 08:00
ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
2026-06-01 08:00
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
2026-06-01 08:00
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
2026-06-01 08:00
Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema
2026-06-01 08:00
United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026
2026-05-31 23:00
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
2026-05-31 21:00
1
2
3
4
5
6
1887